



Introducing Olink® Flex: Immuno-Oncology panel

Accelerating immunotherapy development with blood biomarker profiling


While the ground breaking success of immunotherapy has revolutionized cancer treatment, efforts to better predict responses and increase its efficacy while reducing treatment toxicities remain key challenges in the oncology field.

Patient profiling based on blood biomarkers can have significant clinical value, due to the capacity of circulating proteins to provide real-time insights in a non-invasive, robust, and efficient manner. This approach has shown potential to stratify patients receiving immunotherapy across a range of solid tumors, including melanoma, lung and gastric cancer.

Wider implementation of circulating biomarkers will rely on methods that allow multiplexing with no compromise on data quality. Further validation will lead to more efficient and less invasive strategies for:

- Prediction of treatment response
- Monitoring of treatment efficacy
- Immune-related adverse effects prediction
- Personalized cancer treatments

The Olink Flex Immuno-Oncology panel includes 21 proteins involved in various facets of tumor development and the immune response, out of which biomarkers such as IL8, LIF, IL6, TNF α , IFN γ and CXCL9/10/11 have been shown as clinically relevant for stratifying patients treated with immune checkpoint inhibitors.



Key publications:

- Lorient et al. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. *Annals of Oncology* (2021)
- Sun et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. *Nature* (2023)
- Han et al. Modulation of Inflammatory Proteins in Serum May Reflect Cutaneous Immune Responses in Cancer Immunotherapy. *JID Innovations* (2023)
- Tang et al. Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer. *Cell Reports Med* (2023)
- Gonzalo Nunez et al, Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. *Med* (2023)

Need more flexibility?

Olink® Flex allows you to optimize this panel with other validated assays from the Flex library or to build an entirely new panel that fits your research interests. Try the Flex panel builder on [Olink® Insight](#) now!

